A US pharmaceutical distribution and healthcare services company (NYSE: COR) with a Pune-based India capability center.
cencora.comFounded
2001 (merger of AmeriSource Health and Bergen Brunswig)
Headquarters
Conshohocken, Pennsylvania, USA
Industry
Pharmaceutical distribution and healthcare services
Employees
About 51,000 (2025)
Revenue (FY25)
US$321.33 billionMarket Cap
US$58.97 billion (July 2026)
Listed on
NYSE: COR (S&P 500 component)
CEO
Robert P. Mauch, President and CEO
Website
cencora.com
Cencora, Inc. is a US pharmaceutical distribution and healthcare services company headquartered in Conshohocken, Pennsylvania. It was formed in 2001 through the merger of AmeriSource Health and Bergen Brunswig, operated as AmerisourceBergen Corporation until 2023, and then rebranded to Cencora. The company trades on the New York Stock Exchange under the ticker COR and is a component of the S&P 500.
The business distributes pharmaceutical products and provides related healthcare and commercialization services to pharmacies, health systems, and manufacturers. For fiscal year 2025 Cencora reported revenue of about US$321.33 billion, up roughly 9.3% from the prior year's US$293.96 billion, and it employs around 51,000 people worldwide. As of July 2026 its market capitalization was near US$59 billion.
Cencora runs a capability center in India through Cencora Business Services India Private Limited, incorporated on 24 July 2023 with its registered office in Pune, Maharashtra. The Pune site is described by the company as an India innovation hub supporting information technology, finance, sourcing and procurement, and legal and compliance functions for its global operations.
President and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Executive Vice President and Chief Legal Officer
Chair of the Board of Directors
Interview experience
6 out of 10
Interview difficulty
Easy
Interview process length
About a week
Practice real questions and get instant feedback before the big day.
Q: Name a time you went above and beyond for a customer.
A: Use the STAR method: set the situation, describe the extra step you took, and share the outcome. Pick a moment where you solved a real problem rather than just following policy.
Q: Do you have comparable experience, do you understand the schedule is four 10-hour days, and what are your aspirations with the company?
A: Be honest about your comparable warehouse experience, confirm you can commit to the compressed four-day schedule, and tie your goals to growth inside Cencora's operations.
Q: How many times a year would be an acceptable amount of days to call off work?
A: Employers ask this to gauge reliability. Emphasize strong attendance, that you only call off when genuinely necessary, and that you always give early notice.
Q: Tell me about your background and employment history.
A: Give a short chronological summary of your relevant roles, focusing on warehouse, physical, or safety-related work that maps to this job.
Practice real questions and get instant feedback before the big day.
Average hourly pay
$20.42/hour
171 Salaries submitted
Average hourly pay
$22.38/hour
30 Salaries submitted
Average hourly pay
$21.86/hour
18 Salaries submitted
Average base pay
$77,397/year
34 Salaries submitted
Average base pay
$96,926/year
39 Salaries submitted
Average base pay
$139,766/year
8 Salaries submitted
See how your pay compares and find roles that match your value.
Pune, Maharashtra, India • Full-time
Pune, Maharashtra, India • Full-time
Pune, Maharashtra, India • Full-time
Pune, Maharashtra, India • Full-time
Pune, Maharashtra, India • Full-time
Mumbai, Maharashtra, India • Full-time
Tailor your resume to each Cencora role in minutes.
June 2, 2026
Cencora to support U.S. distribution of Kite's CAR T-cell therapies
Cencora signed an agreement with Kite, a Gilead company, to provide order management, specialty distribution, and cold-chain support for the FDA-approved CAR T-cell therapies Yescarta and Tecartus across U.S. treatment centers. Financial terms weren't disclosed.
#CellTherapy #SpecialtyDistribution #Gilead
View postMay 22, 2026
Cencora updates FY2026 outlook and authorizes $2.0B buyback
Cencora raised its fiscal 2026 adjusted diluted EPS guidance to $17.70 to $17.90 following share repurchases, and its board authorized an additional $2.0 billion share repurchase program. The company reports more than $300 billion in annual revenue.
#Earnings #Guidance #Buyback
View postMay 6, 2026
Cencora reports fiscal 2026 second quarter results
Second-quarter revenue rose 3.8% to $78.4 billion, with adjusted diluted EPS up 7.5% to $4.75. GAAP diluted EPS was $8.40 for the quarter ended March 31, 2026, compared with $3.68 a year earlier.
#Earnings #Q2FY2026 #Revenue
View postMarch 23, 2026
Cencora to acquire EyeSouth Partners' retina business for $1.1B
Cencora announced a definitive agreement to buy EyeSouth Partners' retina business for $1.1 billion, folding its affiliated retina physicians into Retina Consultants of America. The deal isn't expected to close before the September 30 fiscal year-end.
#Acquisition #SpecialtyCare #Retina
View postDecember 15, 2025
Cencora to acquire majority stake in OneOncology
Cencora entered a definitive agreement to buy the majority of equity interests in OneOncology from TPG, valuing the physician-led oncology platform at $7.4 billion enterprise value. Total cash consideration was about $5.0 billion, including retiring $1.3 billion in debt.
#Acquisition #Oncology #SpecialtyCare
View postCencora, Inc. is a US pharmaceutical distribution and healthcare services company. It distributes pharmaceutical products and provides related healthcare and commercialization services to pharmacies, health systems, and manufacturers.
